INmune Bio (NASDAQ:INMB) Upgraded to “Strong-Buy” at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of INmune Bio (NASDAQ:INMBFree Report) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

Other equities analysts also recently issued research reports about the company. Rodman & Renshaw started coverage on INmune Bio in a research report on Tuesday. They issued a “buy” rating and a $23.00 price objective for the company. Alliance Global Partners initiated coverage on shares of INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, INmune Bio has an average rating of “Buy” and a consensus target price of $20.75.

Check Out Our Latest Stock Analysis on INmune Bio

INmune Bio Stock Up 1.8 %

Shares of INMB opened at $9.22 on Tuesday. The company has a 50-day moving average price of $5.62 and a two-hundred day moving average price of $6.08. The stock has a market cap of $204.43 million, a price-to-earnings ratio of -4.23 and a beta of 1.78. INmune Bio has a 12 month low of $4.32 and a 12 month high of $14.74.

INmune Bio (NASDAQ:INMBGet Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same quarter in the prior year, the business posted ($0.48) EPS. Equities research analysts expect that INmune Bio will post -2.24 EPS for the current fiscal year.

Institutional Trading of INmune Bio

A number of hedge funds have recently modified their holdings of INMB. Praetorian PR LLC increased its stake in INmune Bio by 61.0% in the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after purchasing an additional 295,800 shares in the last quarter. Geode Capital Management LLC increased its position in shares of INmune Bio by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock valued at $1,857,000 after buying an additional 21,262 shares in the last quarter. State Street Corp raised its stake in INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after buying an additional 58,838 shares during the period. Marshall Wace LLP lifted its holdings in INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares in the last quarter. Finally, Westside Investment Management Inc. grew its stake in INmune Bio by 26.2% in the fourth quarter. Westside Investment Management Inc. now owns 89,975 shares of the company’s stock valued at $420,000 after acquiring an additional 18,660 shares during the period. 12.72% of the stock is currently owned by institutional investors and hedge funds.

About INmune Bio

(Get Free Report)

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Further Reading

Analyst Recommendations for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.